Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Chemotherapy, Radiation, Immunotherapy, Surgery.

Nihon University School of Medicine, Tokyo, Japan.

Survival: monthsCountry:Japan
Toxiciy Grade:3City/State/Province:Tokyo
Treatments:Chemotherapy, Radiation, Immunotherapy, SurgeryHospital:Nihon University School of Medicine
Drugs:Journal:Link
Date:Mar 2005

Description:

Patients: This trial involved 58 patients: 22 had anaplastic astrocytoma, and 36 had glioblastoma multiforme. Thirty-four patients were men, and twenty-four were women. Overall, the median age was 53 years.

Treatment: The treatment consisted of surgery, radiation therapy, the immunotherapeutic agent human interferon beta (IFN-b), and the chemotherapeutic agent nimustine hydrochloride.

Toxicity: No grade 4 toxicities were reported. Grade 3 toxicities included neutropenia.

Results: The median overall survival was 16 months. For anaplastic astrocytoma patients, the median survival was 58 months. For glioblastoma multiforme patients, the median survival was 13 months. The authors concluded that post-surgery interferon-nimustine-radiation treatment may have therapeutic benefit for anaplastic astrocytoma patients.

Correspondence: Takao Watanabe, MD




Back